An open clinical study of tebipenem pivoxil in children with bacterial pneumonia

Satoshi Iwata, Kazunobu Ouchi, Naoichi Iwai, Akira Watanabe, Kyoichi Totsuka, Seiji Hori, Yoshio Aizawa, Kimiko Ubukuta, Keisuke Sunakawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We conducted an open clinical study of a new oral carbapenem antibacterial agent, tebipenem pivoxil (TBPM-PI), in pediatric patients with bacterial pneumonia to assess efficacy, safety, medication compliance, and pharmacokinetics. Dosage and administration were 4 mg/kg bid or 6 mg/kg bid, and treatment was 7 days. Clinical efficacy in 59 subjects was 98.3% (58/59), and efficacy by treatment group was 100% (35/35) in the 4 mg/kg bid group and 95.8% (23/ 24) in the 6 mg/kg bid group. In 10 subjects from whom sputum could be collected, sputum had disappeared by the end of administration. Bacteriological eradication was 100% (16/16). Isolation frequency was high for Streptococcus pneumoniae (5 strains) and Haemophilus influenzae (9 strains) as causative organisms. The incidence of drug-related adverse reactions associated with subjective symptoms/objective findings in 66 subjects for safety analysis was 40.0% (16/40) in the 4 mg/kg bid group and 30.8% (8/26) in the 6 mg/kg bid group. The incidence of drug-related adverse reactions associated with abnormal changes in laboratory data was 10.0% (4/40) in the 4 mg/kg bid group and 11.5% (3/26) in the 6 mg/kg bid group, showing no increase in incidence with dosage increase. Common adverse drug reactions included stools watery, mushy stool, loose bowel, and platelet count increase. No severe or serious adverse drug reactions were seen. Drug compliance in both groups was 89.4% (59/66), and no administration was judged "Hard to take" or "Unable to take." Concerning pharmacokinetics in 65 subjects for whom plasma TBPM concentrations could be measured, Cmax and AUC0-24h increased with dosage. No difference in Tmax or t1/2 depended on dosage. Results suggest that TBPM-PI could be expected to show high efficacy at 4 mg/kg bid in pediatric patients with bacterial pneumonia and no significant safety problems. High efficacy was shown in patients requiring a high dose and given 6 mg/kg bid despite high CRP, WBC, and detection of resistant strains, and administration of 6 mg/kg bid was judged to be useful depending on symptom and severity.

Original languageEnglish
Pages (from-to)137-150
Number of pages14
JournalJapanese Journal of Chemotherapy
Volume57
Issue numberSUPPL. 1
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

Bacterial Pneumonia
Drug-Related Side Effects and Adverse Reactions
Sputum
Safety
Incidence
Pharmacokinetics
Pediatrics
Carbapenems
Medication Adherence
Haemophilus influenzae
Streptococcus pneumoniae
Platelet Count
Anti-Bacterial Agents
Clinical Studies
tebipenem
Pharmaceutical Preparations
Therapeutics

Keywords

  • Bacterial pneumonia
  • Child
  • Oral carbapenem
  • Tebipenem pivoxil

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Iwata, S., Ouchi, K., Iwai, N., Watanabe, A., Totsuka, K., Hori, S., ... Sunakawa, K. (2009). An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Japanese Journal of Chemotherapy, 57(SUPPL. 1), 137-150.

An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. / Iwata, Satoshi; Ouchi, Kazunobu; Iwai, Naoichi; Watanabe, Akira; Totsuka, Kyoichi; Hori, Seiji; Aizawa, Yoshio; Ubukuta, Kimiko; Sunakawa, Keisuke.

In: Japanese Journal of Chemotherapy, Vol. 57, No. SUPPL. 1, 03.2009, p. 137-150.

Research output: Contribution to journalArticle

Iwata, S, Ouchi, K, Iwai, N, Watanabe, A, Totsuka, K, Hori, S, Aizawa, Y, Ubukuta, K & Sunakawa, K 2009, 'An open clinical study of tebipenem pivoxil in children with bacterial pneumonia', Japanese Journal of Chemotherapy, vol. 57, no. SUPPL. 1, pp. 137-150.
Iwata S, Ouchi K, Iwai N, Watanabe A, Totsuka K, Hori S et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Japanese Journal of Chemotherapy. 2009 Mar;57(SUPPL. 1):137-150.
Iwata, Satoshi ; Ouchi, Kazunobu ; Iwai, Naoichi ; Watanabe, Akira ; Totsuka, Kyoichi ; Hori, Seiji ; Aizawa, Yoshio ; Ubukuta, Kimiko ; Sunakawa, Keisuke. / An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. In: Japanese Journal of Chemotherapy. 2009 ; Vol. 57, No. SUPPL. 1. pp. 137-150.
@article{d7335c4b725e4470b2d3a9aa2f81f387,
title = "An open clinical study of tebipenem pivoxil in children with bacterial pneumonia",
abstract = "We conducted an open clinical study of a new oral carbapenem antibacterial agent, tebipenem pivoxil (TBPM-PI), in pediatric patients with bacterial pneumonia to assess efficacy, safety, medication compliance, and pharmacokinetics. Dosage and administration were 4 mg/kg bid or 6 mg/kg bid, and treatment was 7 days. Clinical efficacy in 59 subjects was 98.3{\%} (58/59), and efficacy by treatment group was 100{\%} (35/35) in the 4 mg/kg bid group and 95.8{\%} (23/ 24) in the 6 mg/kg bid group. In 10 subjects from whom sputum could be collected, sputum had disappeared by the end of administration. Bacteriological eradication was 100{\%} (16/16). Isolation frequency was high for Streptococcus pneumoniae (5 strains) and Haemophilus influenzae (9 strains) as causative organisms. The incidence of drug-related adverse reactions associated with subjective symptoms/objective findings in 66 subjects for safety analysis was 40.0{\%} (16/40) in the 4 mg/kg bid group and 30.8{\%} (8/26) in the 6 mg/kg bid group. The incidence of drug-related adverse reactions associated with abnormal changes in laboratory data was 10.0{\%} (4/40) in the 4 mg/kg bid group and 11.5{\%} (3/26) in the 6 mg/kg bid group, showing no increase in incidence with dosage increase. Common adverse drug reactions included stools watery, mushy stool, loose bowel, and platelet count increase. No severe or serious adverse drug reactions were seen. Drug compliance in both groups was 89.4{\%} (59/66), and no administration was judged {"}Hard to take{"} or {"}Unable to take.{"} Concerning pharmacokinetics in 65 subjects for whom plasma TBPM concentrations could be measured, Cmax and AUC0-24h increased with dosage. No difference in Tmax or t1/2 depended on dosage. Results suggest that TBPM-PI could be expected to show high efficacy at 4 mg/kg bid in pediatric patients with bacterial pneumonia and no significant safety problems. High efficacy was shown in patients requiring a high dose and given 6 mg/kg bid despite high CRP, WBC, and detection of resistant strains, and administration of 6 mg/kg bid was judged to be useful depending on symptom and severity.",
keywords = "Bacterial pneumonia, Child, Oral carbapenem, Tebipenem pivoxil",
author = "Satoshi Iwata and Kazunobu Ouchi and Naoichi Iwai and Akira Watanabe and Kyoichi Totsuka and Seiji Hori and Yoshio Aizawa and Kimiko Ubukuta and Keisuke Sunakawa",
year = "2009",
month = "3",
language = "English",
volume = "57",
pages = "137--150",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - An open clinical study of tebipenem pivoxil in children with bacterial pneumonia

AU - Iwata, Satoshi

AU - Ouchi, Kazunobu

AU - Iwai, Naoichi

AU - Watanabe, Akira

AU - Totsuka, Kyoichi

AU - Hori, Seiji

AU - Aizawa, Yoshio

AU - Ubukuta, Kimiko

AU - Sunakawa, Keisuke

PY - 2009/3

Y1 - 2009/3

N2 - We conducted an open clinical study of a new oral carbapenem antibacterial agent, tebipenem pivoxil (TBPM-PI), in pediatric patients with bacterial pneumonia to assess efficacy, safety, medication compliance, and pharmacokinetics. Dosage and administration were 4 mg/kg bid or 6 mg/kg bid, and treatment was 7 days. Clinical efficacy in 59 subjects was 98.3% (58/59), and efficacy by treatment group was 100% (35/35) in the 4 mg/kg bid group and 95.8% (23/ 24) in the 6 mg/kg bid group. In 10 subjects from whom sputum could be collected, sputum had disappeared by the end of administration. Bacteriological eradication was 100% (16/16). Isolation frequency was high for Streptococcus pneumoniae (5 strains) and Haemophilus influenzae (9 strains) as causative organisms. The incidence of drug-related adverse reactions associated with subjective symptoms/objective findings in 66 subjects for safety analysis was 40.0% (16/40) in the 4 mg/kg bid group and 30.8% (8/26) in the 6 mg/kg bid group. The incidence of drug-related adverse reactions associated with abnormal changes in laboratory data was 10.0% (4/40) in the 4 mg/kg bid group and 11.5% (3/26) in the 6 mg/kg bid group, showing no increase in incidence with dosage increase. Common adverse drug reactions included stools watery, mushy stool, loose bowel, and platelet count increase. No severe or serious adverse drug reactions were seen. Drug compliance in both groups was 89.4% (59/66), and no administration was judged "Hard to take" or "Unable to take." Concerning pharmacokinetics in 65 subjects for whom plasma TBPM concentrations could be measured, Cmax and AUC0-24h increased with dosage. No difference in Tmax or t1/2 depended on dosage. Results suggest that TBPM-PI could be expected to show high efficacy at 4 mg/kg bid in pediatric patients with bacterial pneumonia and no significant safety problems. High efficacy was shown in patients requiring a high dose and given 6 mg/kg bid despite high CRP, WBC, and detection of resistant strains, and administration of 6 mg/kg bid was judged to be useful depending on symptom and severity.

AB - We conducted an open clinical study of a new oral carbapenem antibacterial agent, tebipenem pivoxil (TBPM-PI), in pediatric patients with bacterial pneumonia to assess efficacy, safety, medication compliance, and pharmacokinetics. Dosage and administration were 4 mg/kg bid or 6 mg/kg bid, and treatment was 7 days. Clinical efficacy in 59 subjects was 98.3% (58/59), and efficacy by treatment group was 100% (35/35) in the 4 mg/kg bid group and 95.8% (23/ 24) in the 6 mg/kg bid group. In 10 subjects from whom sputum could be collected, sputum had disappeared by the end of administration. Bacteriological eradication was 100% (16/16). Isolation frequency was high for Streptococcus pneumoniae (5 strains) and Haemophilus influenzae (9 strains) as causative organisms. The incidence of drug-related adverse reactions associated with subjective symptoms/objective findings in 66 subjects for safety analysis was 40.0% (16/40) in the 4 mg/kg bid group and 30.8% (8/26) in the 6 mg/kg bid group. The incidence of drug-related adverse reactions associated with abnormal changes in laboratory data was 10.0% (4/40) in the 4 mg/kg bid group and 11.5% (3/26) in the 6 mg/kg bid group, showing no increase in incidence with dosage increase. Common adverse drug reactions included stools watery, mushy stool, loose bowel, and platelet count increase. No severe or serious adverse drug reactions were seen. Drug compliance in both groups was 89.4% (59/66), and no administration was judged "Hard to take" or "Unable to take." Concerning pharmacokinetics in 65 subjects for whom plasma TBPM concentrations could be measured, Cmax and AUC0-24h increased with dosage. No difference in Tmax or t1/2 depended on dosage. Results suggest that TBPM-PI could be expected to show high efficacy at 4 mg/kg bid in pediatric patients with bacterial pneumonia and no significant safety problems. High efficacy was shown in patients requiring a high dose and given 6 mg/kg bid despite high CRP, WBC, and detection of resistant strains, and administration of 6 mg/kg bid was judged to be useful depending on symptom and severity.

KW - Bacterial pneumonia

KW - Child

KW - Oral carbapenem

KW - Tebipenem pivoxil

UR - http://www.scopus.com/inward/record.url?scp=65249148488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249148488&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:65249148488

VL - 57

SP - 137

EP - 150

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -